AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02560467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Echo and myocardial contrast echocardiography perfusion imaging
Description: Myocardial blood flow will be assessed by myocardial contrast echo. Perfusion at rest and stress will be quantified and compared to patient sx, degree of dysfunction on echo strain imaging, and degree of fibrosis on magnetic resonance imaging (when available) that was ordered as part of routine clinical care.~Myocardial contrast echocardiography will be performed by intravenous administration of ultrasound contrast agent (Definity or Lumason) using FDA-approved dose limits. Vasodilator stress during MCE imaging will be performed using regadenoson at FDA-approved doses.
Study NCT03710811 — intervention group
Intervention type: DRUG
Intervention: Insulin
Description: Continuous Subcutaneous Insulin Infusion
Study NCT02319369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan
Description: Milademetan will be administered daily as oral capsules or as a combination of multiple oral capsules containing 5, 20, 80, and/or 200 mg. An alternate combination of 30 mg, 80 mg, and/or 100 mg milademetan may be utilized.
Study NCT02340650 — intervention group
Intervention type: DEVICE
Intervention: Standard High Resolution Microendoscope and/or Line-Scanning Confocal High Resolution Microendoscope
Study NCT01479608 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver transplantation and liver resection
Study NCT02323022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IAC regimen
Description: Induction treatment for initially diagnosed AML with IAC regimen, including Cladribine 5mg/msq/d (d1-5), Ara-C 100mg/msq/d(d1-7) and IDA 8mg/msq/d (d1-3)
Study NCT02323022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IA regimen
Description: Induction treatment for initially diagnosed AML with IAC regimen, including Ara-C 100mg/msq/d (d1-7) and IDA 12mg/msq/d (d1-3)
Study NCT04149314 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HPI based hemodynamic optimization algorithm
Description: Interventional patients will be treated by a HPI-based hemodynamic optimization protocol including HPI, Stroke volume, cardiac index and mean arterial pressure.
Study NCT01503216 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: cholecalciferol, 2000 IU per day, 8 weeks
Study NCT01503216 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ergocalciferol
Description: vitamin d2, 2000 IU per day for 8 weeks
Study NCT01503216 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03326934 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dark chocolate
Description: Trader Joe's 72% Cacao Dark Chocolate bar, 47g, 34g cacao, total flavanols: 316.3 mg.
Study NCT03326934 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Milk Chocolate
Description: Trader Joe's Crispy Rice Milk Chocolate bar: 40g, 12.4g milk chocolate cocoa; total flavanols: 40 mg.
Study NCT03471026 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Advanced MRI sequences
Description: Structural, diffusion and perfusion MRI sequences
Study NCT02792868 — intervention group
Intervention type: OTHER
Intervention: 24 h urines analyses
Description: patient collects urines during 24h
Study NCT03369795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate 10mg once a week will be given for the first two weeks of the trial, followed by an increase in dose to 15mg or equivalent placebo once a week until week 16.
Study NCT03369795 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Arm
Description: Pills equivalent to the study drug arm (10mg) will be given once a week for the first two weeks of the trial, followed by an increase in dose to 15mg of equivalent placebo once a week until week 16.
Study NCT01349348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: tablet, 15 mg, Qd, for 7 days
Study NCT01349348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: tablet, 7.5 mg, Qd, for 7 days
Study NCT01349348 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablet, 7.5/15mg , Qd, 7days.
Study NCT01245348 — intervention group
Intervention type: GENETIC
Intervention: SULT4A1-1 genetic test
Description: SULT4A1-1 haplotype result (+/-)
Study NCT01246492 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Artificial Sweeteners
Description: A 400mL drink sweetened with 45g glucose and artificial sweetener will be consumed orally
Study NCT01246492 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Artificial Sweeteners
Description: A 400mL drink sweetened with 45g glucose and artificial sweetener will be consumed orally
Study NCT03681145 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counselor delivered telehealth intervention
Description: This is a technology-based counseling intervention for youth living with HIV (YLWH) focused on engagement in HIV care, mental health, and substance use challenges through text messaging and teleconferencing (telehealth). The intervention is delivered in 12 brief sessions.
Study NCT02226666 — intervention group
Intervention type: DRUG
Intervention: MRI with Multihance
Description: Patients will have Multihance used as an IV contrast agent for their scan.
Study NCT02226666 — intervention group
Intervention type: DRUG
Intervention: MRI with Eovist
Description: Patients will have Eovist used as an IV contrast agent for their scan.
Study NCT05231967 — intervention group
Intervention type: OTHER
Intervention: Cardioversion
Description: In proper atrial fibrillation patients, cardioversion was performed to provide sinus rhythm
Study NCT03404648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-11 choline PET tracer
Description: C-11 choline PET tracer, One dose, totally 12-14 millicurie (mCi), intravenous administration while patient is lying on the table.
Study NCT03404648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol
Description: Single dose of Gadavist® (Gadobutrol, Bayer) at no more than 0.1 mmol/kg will be administrated intravenously.
Study NCT03404648 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MR scanner
Description: C11-PET/MR and pelvic mpMRI scan for prostate cancer.
Study NCT03333473 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PPFP Clinical and Counseling Skills
Description: Facilities will receive whole-site orientations on PPFP basics and skills Through training of trainers, followed by classroom and model-based and clinical-based practice, providers will receive training in PPDP counseling and service provision.
Study NCT03333473 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facility-Level Leadership Management and Governance Training
Description: The intervention will strengthen leadership management and governance practices required to help managers establish PPFP services at the facility level.
Study NCT00393718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 0.9 mg/day. Injected s.c. (under the skin) once daily.
Study NCT00393718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glibenclamide
Description: 1.25-2.5 mg tablet. Given orally once or twice daily.
Study NCT00393718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: liraglutide placebo. Injected s.c. (under the skin) once daily.
Study NCT00393718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: glibenclamide placebo. Given orally once or twice daily.
Study NCT02531815 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06741086
Description: PF-06741086, single dose, beginning with Cohort 1 dose level at 30 mg. Subsequent dose levels will be determined after data review of prior cohort(s)
Study NCT02531815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for PF-06741086, single dose
Study NCT00123929 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: docetaxel
Description: 100 mg/m2 every 3 weeks times 4
Study NCT00123929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin
Description: 75 mg/m2 every 3 weeks times 4
Study NCT00144170 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tipranavir (with low dose ritonavir)
Study NCT00144170 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Comparator protease inhibitor(CPI)/low dose ritonavir(r)
Study NCT02160457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention with IGA
Description: Individually tailored interdisciplinary intervention based on measures performed as part of the Cerebral Palsy follow-Up Program and other clinical examinations AND instrumented gait analysis~The instrumented gait analysis consists of four steps:~1. Instrumented gait analysis (data collection with a 8-camera Vicon T40 system (Vicon, Oxford, UK) and 2 force plates (AMTI, OR6-7-1000)~2. Impairment-Focused Interpretation~3. Recommendation for interdisciplinary interventions~4. Dissemination of recommendations~The two modalities differs in the use of IGA, but the study is not indented to document the effect of IGA alone, but to document the difference in the effects of the interdisciplinary interventions, when IGA is implemented to the experimental group.
Study NCT00981526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: Telmisartan 40mg/day for the first 2 weeks.~Telmisartan 80mg/day for the next 10 weeks.
Study NCT00981526 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (plus existing clozapine or olanzapine treatment) for 12 weeks.
Study NCT01091259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study NCT01091259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT00469547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 62% ethanol in emollient gel
Description: 62% ethanol in emollient gel used as a topical male microbicide
Study NCT00469547 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 15% ethanol in emollient gel used as a topical male microbicide
Study NCT00469547 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 15% ethanol in emollient gel
Description: 15% ethanol in emollient gel used as a topical male microbicide
Study NCT03035019 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lantern
Description: This pilot will evaluate how the availability of a virtual stress management resource can help patients reduce anxiety and improve quality of life.
Study NCT00981526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Description: Clozapine (plus telmisartan or placebo) for 12 weeks.
Study NCT00981526 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clozapine
Description: Clozapine (plus telmisartan or placebo) for 12 weeks.
Study NCT00981526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine (plus telmisartan or placebo) for 12 weeks.
Study NCT00981526 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine (plus telmisartan or placebo) for 12 weeks.
Study NCT03394638 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Access to online eLearning module
Description: Patients enrolled in the Online group have access to an online platform called BePatient. Patients are given the ability to access the platform and do eLearnings; watch videos about the operation and recovery; do quizzes, see dietary advices; see news about obesity and our department; read patients' stories. They are also able to chat with other patients.
Study NCT03394638 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Access to measurement devices
Description: Patients in the device group have, in addition to patients in the Online group, access to 4 measuring devices, including: weight scale, oximeter, activity bracelet and blood pressure device. Those devices are connectable to their mobile phones where patients can view their own progress.
Study NCT03394638 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional group
Description: All patients undergo the standard of care which included: the bariatric procedure and several outpatient visits including consultation with their surgeon, obesity nurses, dieticians and (if indicated) psychologists.
Study NCT03394638 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional group
Description: All patients undergo the standard of care which included: the bariatric procedure and several outpatient visits including consultation with their surgeon, obesity nurses, dieticians and (if indicated) psychologists.
Study NCT02272790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib
Description: Adavosertib will be taken as oral capsules with water, approx. 2 hours before or 2 hours after food.
Study NCT02272790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered as a 1-hour IV infusion (± 10 minutes) at a dose of 80 mg/m2 according to institutional standards on Days 1, 8, and 15 of each 28 Day cycle.~Patients should be pre-medicated with corticosteroids, diphenhydramine and/or H2 antagonists according to institutional standards.
Study NCT01655160 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MT with low-intensity group (MT-LI)
Description: The MT-LI group will receive a 30-minute MT per session followed by a 30-minute functional training.
Study NCT02272790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin, at a dose calculated to produce an AUC of 5 will be administered by intravenous infusion according to institutional standards on Day 1 of each 21 Day cycle. The carboplatin dose will be calculated using the Calvert Formula based on the patient's glomerular filtration rate (GFR) which is estimated by using the creatinine clearance.
Study NCT02272790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 800 mg/m² will be administered IV on Days 1, 8, and 15 of each 28-Day cycle.
Study NCT02272790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLD
Description: PLD (pegylated liposomal doxorubicin) 40 mg/m² IV will be given on Day 1 of each 28-Day cycle.
Study NCT02066064 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Colonoscopy
Description: Standard Colonoscopy
Study NCT02066064 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Colonoscopy
Description: Standard Colonoscopy
Study NCT02066064 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: G-EYE(TM) Colonoscopy
Description: G-EYE(TM) Colonoscopy
Study NCT02066064 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: G-EYE(TM) Colonoscopy
Description: G-EYE(TM) Colonoscopy
Study NCT01569581 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 100U/0.5ml in 6-11 months old infants
Description: inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1750 infants aged 6-11 months old on day 0, 28
Study NCT01569581 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 100U/0.5ml in 12-23 months old infants
Description: inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1750 infants aged 12-23 months old on day 0, 28
Study NCT01569581 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 100U/0.5ml in 24-35 months old children
Description: inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1500 children aged 24-35 months old on day 0, 28
Study NCT01569581 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 100U/0.5ml in 36-71 months old children
Description: inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1000 children aged 36-71 months old on day 0, 28
Study NCT00702143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir F 18
Description: IV injection, 370MBq (10mCi), single dose
Study NCT04439890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride capsule
Description: Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
Study NCT04439890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin injection
Description: Carboplatin injection AUC 5mg/mL/min, intravenous drip, on Day 1 in 21-day cycle.
Study NCT04439890 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin injection
Description: Carboplatin injection AUC 5mg/mL/min, intravenous drip, on Day 1 in 21-day cycle.
Study NCT01655160 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MT with moderate-intensity group
Description: The MT-MI group will receive a 60-minute MT per session followed by a 30-minute functional training.
Study NCT01655160 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror therapy with high intensity group
Description: The MT-HI group will receive a 90-minute MT per session followed by a 30-minute functional training
Study NCT04439890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed disodium f Injection
Description: Pemetrexed disodium f Injection 500mg / m2, intravenous drip, on Day 1 in 21-day cycle.
Study NCT03996369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod
Description: Etrasimod 2 mg tablet by mouth, once daily up to 12-Week Induction Treatment Period
Study NCT04439890 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed disodium f Injection
Description: Pemetrexed disodium f Injection 500mg / m2, intravenous drip, on Day 1 in 21-day cycle.
Study NCT04439890 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02901171 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT group treatment combined with smartphone application
Description: The Acceptance and Commitment Therapy (ACT) group treatment for smoking cessation will be delivered in six weekly 90-min sessions. Smoking cessation will be promoted in each session by targeting core processes of the ACT model including acceptance, cognitive defusion, mindfulness, flexible perspective taking, values clarification and committed action. In addition, participants will receive an ACT-based smartphone application for smoking cessation. The application will foster core processes of the ACT model through daily exercises, tips and tools.
Study NCT02901171 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ACT group treatment
Study NCT02901171 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group based Behavioural Support Programme
Description: The Behavioural Support Programme will be facilitated by stop smoking experts and delivered in six weekly 90-min sessions in a group format. During the sessions, advice, support and information on smoking cessation will be given to participants and behavioural techniques will be reviewed.
Study NCT02800174 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart nitinol stent implantation
Description: Before intervention, clopidogrel (75 mg/d), aspirin (100 mg/d) and atorvastatin (40 mg/d) were prescribed. One week later, aortic arch and aortocranial angiography were performed under general anesthesia to determine the site, range and extent of the lesion and the status of the cerebral microcirculation, and consequently to inform the treatment strategy and the selection of the correct size of self-expanding nitinol stent system.
Study NCT02800174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antiplatelet drug
Description: Patients with carotid artery stenosis treated conservatively were commenced on an indefinite course of one or more oral antiplatelet drugs. The antiplatelet regimes comprised 100 mg or 300 mg aspirin before sleep with clopidogrel 125 mg or 250 mg daily; or 75 mg clopidogrel before sleep daily.
Study NCT03996369 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Etrasimod matching placebo tablet by mouth, once daily up to 12-Week Induction Treatment Period
Study NCT03814421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intermittent (40mg as a bolus injection daily for 72hours)
Description: Current guidelines recommend an intravenous bolus dose of a proton pump inhibitor(PPI) followed by continuous PPI infusion after endoscopic therapy in patients with high-risk bleeding peptic ulcers. However, recent many studies suggests intermittent low dose PPI infusion might have equal efficacy at preventing peptic ulcer hemorrhage recurrence. So, the present investigator assumed that intermittent administration of proton pump inhibitor will not be different from administration of continuous proton pump inhibitor for the prevention of rebleeding in patients with peptic ulcer bleeding. Also, intermittent proton pump inhibitor administration in patients with high risk of rebleeding (Rockall score 6 points or more) will not be different from prevention of rebleeding compared with continuous proton pump inhibitor administration.